Crescent Biopharma Quarterly Balance Sheet
NASDAQ: CBIOHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Crescent Biopharma financial position
As of Jun 30, 2026, Crescent Biopharma reported total assets of $182.8 million, up 16.1% from a year earlier against total liabilities of $19.5 million. Shareholders' equity stood at $163.3 million, or 89.3% of assets. The company held $171.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.66, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Crescent Biopharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 171.59M | 189.16M | 213.19M | 133.26M | 152.65M | 22.43M | 34.77M | 14.39M | 22.39M | 31.28M | 41.79M | 49.41M |
| Receivables | 0 | 0 | 18.00M | — | — | — | 0 | — | — | — | — | — |
| Total Current Assets | 179.01M | 195.56M | 236.66M | 134.56M | 154.23M | 5.99M | 34.80M | 15.65M | 23.86M | 33.27M | 43.79M | 52.01M |
| Property, Plant & Equipment | 876.00K | 929.00K | 846.00K | 782.00K | 193.00K | — | 0 | — | — | — | — | 132.98K |
| Total Assets | 182.76M | 199.13M | 240.29M | 138.27M | 157.43M | 5.99M | 35.62M | 15.70M | 24.42M | 34.20M | 45.32M | 53.20M |
| Accounts Payable | — | — | — | — | — | 104.67K | 329.30K | 581.79K | 950.76K | 755.53K | 868.12K | 329.88K |
| Total Current Liabilities | 18.54M | 14.19M | 36.07M | 20.30M | 16.75M | 2.62M | 9.61M | 4.32M | 4.36M | 5.29M | 6.84M | 6.39M |
| Long-Term Debt | — | — | 0 | 0 | 0 | — | 37.48M | — | — | — | — | — |
| Total Liabilities | 19.50M | 15.28M | 37.28M | 21.63M | 18.18M | 2.62M | 47.10M | 4.32M | 4.36M | 5.29M | 6.90M | 6.65M |
| Shareholders' Equity | 163.25M | 183.85M | 203.01M | 116.64M | 139.25M | -30.16M | -15.48M | -1.30M | 20.06M | 28.91M | 38.41M | 46.55M |
| Retained Earnings | -219.93M | -195.09M | -171.81M | -79.41M | -54.80M | -496.71M | -17.87M | -487.14M | -477.32M | -467.22M | -456.49M | -447.41M |
| Total Debt | — | — | 0 | 0 | 0 | — | 37.48M | — | — | — | — | — |
| Net Cash (Debt) | 171.59M | 189.16M | 213.19M | 133.26M | 152.65M | 22.43M | -2.72M | 14.39M | 22.39M | 31.28M | 41.79M | 49.41M |
| Shares Outstanding | 27.76M | 27.57M | 27.56M | 13.89M | 13.89M | 64.53M | 1.02M | 64.48M | 64.48M | 64.45M | 64.39M | 64.37M |
This table shows 12 quarterly periods of Crescent Biopharma's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, receivables, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CBIO's reporting calendar. What is a balance sheet?